Epigenetic regulation of chromatin structure is fundamental to establish and maintain cell type-specific gene expression during development and disease states (1, 2). Importantly, acetylation and methylation of histone tails and methylation of DNA by a specific group of enzymes are the most common epigenetic modifications that occur at specific sites and residues (3). For example, histone acetyltransferases acetylate histone tails, histone deacetylases remove acetyl groups from histone tails, and BRD (bromodomain) proteins are chromatin readers that recognize and bind acetylated histones. The latter also play a key role in the transmission of epigenetic memory across cell divisions and transcription regulation, and thus have emerged as an attractive drug class for the treatment of cancer and other nonmalignant disorders (4–6).

Pulmonary arterial hypertension (PAH; group 1 pulmonary hypertension [PH]) is a progressive pulmonary vascular disease with a poor prognosis that culminates in right heart failure. Despite our progressive understanding of the pathogenesis of PAH and recent therapeutic advances, PAH remains a fatal disease (7). Several lines of evidence suggest the contribution of epigenetic mechanisms to vascular remodeling in PH/PAH. First, both the initiation and progression of PH/PAH are influenced by environmental factors, and thus it has been speculated that exposure to viruses, drugs, toxins, hypoxia, and inflammation drives epigenetic mechanisms underlying PH/PAH pathogenesis. Second, PAH is also a genetic disease, and genetic factors also influence epigenetic mechanisms. Third, epigenetic modifications are also crucial for the persistent activation of PAH vascular cells when cultured ex vivo, a hallmark feature of PAH. Finally, emerging evidence suggests that the pathogenesis of PH is influenced by aberrant expression and activity of DNA and histone-modifying enzymes (8, 9), including upregulation of BRD4. Accordingly, earlier studies demonstrated that pan-BRD (JQ1 and I-BET-151) and selective BRD4 knockdown inhibited pulmonary arterial smooth muscle cell proliferation and restored mitochondrial membrane potential in patients with PAH (10), and prevented the production of proinflammatory cytokines by pulmonary microvascular endothelial cells (11). Importantly, studies showed that pan-BRD inhibitors reversed established PAH in the Sugen/hypoxia and hypoxia/pulmonary inflammation rat models (10, 12). However, in contrast to these promising studies, Piquereau and colleagues found that Wistar rats and C57Bl/6J mice treated with I-BET-151 for 3 weeks developed cardiomyopathy as demonstrated by progressive mitochondrial damage and a global reduction in cardiac function (13). The conflicting data from these studies can be understood in light of the wide-ranging effects that BETs have in reprogramming the epigenome and off-target effects. Thus, domain- and isoform-specific BET (bromodomain and extraterminal motif) inhibitors are highly needed to avoid the adverse effects of prolonged pan-BET inhibition.

In the setting of a multicenter preclinical trial, Van der Feen and colleagues report that apabetalone (RXV-208), a clinically available domain-selective BET inhibitor, reversed vascular remodeling and improved pulmonary hemodynamics in several experimental models of PAH (14). This study provides convincing data, obtained both in vitro and in vivo, indicating that apabetalone normalized the hyperproliferative, apoptosis-resistant and proinflammatory phenotype of microvascular endothelial cells and pulmonary arterial smooth muscle cells isolated from patients with PAH, as well as in animal models of PAH (Figure 1). Importantly, at a clinically relevant dose, RXV-208 reversed vascular remodeling in multiple complementary preclinical models of PAH and could be combined safely with current PAH therapy. Finally, apabetalone was shown to support the pressure-loaded right ventricle in rats, indicating a beneficial, dual mode of action for patients with PAH-associated right-ventricle pressure overload. Based on these exciting preclinical results, a 16-week phase 2 pilot study (ClinicalTrials.gov identifier: NCT02780818) is ongoing.
on whether it shows disease-modifying effects in combination with U.S. Food and Drug Administration–approved therapies. It should be stressed that no BRD inhibitor has been granted Food and Drug Administration approval thus far, but several drugs have been or are currently in clinical trials. The attractive therapeutic potential of BET inhibition continues to draw the interest of academic researchers and drug companies. The major challenge in developing new BET inhibitors will be to maximize therapeutic efficacy while reducing toxicity. Cancer studies have demonstrated that BET inhibitors work better in combination with other antiproliferative compounds such as PDI inhibitors and tyrosine kinase inhibitors, another drug class that has been investigated in PAH in recent years (19). Furthermore, new strategies, such as protein-targeting chimeric molecules for BRDs, have already been developed and have shown promising activity on cancer cell lines (20). Independently of the results of the ongoing apabetalone study, BET inhibition remains an attractive mechanism for drug development, and it is hoped that in the coming years this approach will prove to be successful for treatment of PAH. Moreover, it is important to emphasize that studies to assess the role of domain- and isoform-selective inhibitors, as well as each BET protein, in regulating specific biological roles, gene transcription, transcription factor interactions, and the epigenome on a genome-wide scale using RNA sequencing, chromatin immunoprecipitation sequencing, and proteomic approaches are warranted.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Soni Savai Pullamsetti, Ph.D.*
Max Planck Institute for Heart and Lung Research, member of the German Center for Lung Research
Bad Nauheim, Germany

Justus Liebig University
Giessen, Germany

Vinicio A. de Jesus Perez, M.D.
Stanford University
Palo Alto, California

*Corresponding author (e-mail: soni.pullamsetti@innere.med.uni-giessen.de).

References

1. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33:245–254.
2. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693–705.
3. Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 2007;14:1008–1016.
4. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012;11:384–400.
5. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 2014;13:337–356.
6. Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol 2017;18:246–262.
7. Pullamsetti SS, Schermuly R, Ghofrani A, Weissmann N, Grimminger F, Seeger W. Novel and emerging therapies for pulmonary hypertension. Am J Respir Crit Care Med 2014;189:394–400.
8. Pullamsetti SS, Perros F, Chelladurai P, Yuan J, Stenmark K. Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series). Pulm Circ 2016;6:448–464.

9. Gamien E, Seeger W, Pullamsetti SS. The emerging role of epigenetics in pulmonary hypertension. Eur Respir J 2016;48:903–917.

10. Melojo J, Potus F, Vaillancourt M, Bourgeois A, Johnson I, Deschamps L, et al. Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension. Circ Res 2015;117:525–535.

11. Mumbay S, Gambaryan N, Meng C, Perros F, Humbert M, Wotr SJ, et al. Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: implications for pulmonary arterial hypertension. Respirol 2017;22:157–164.

12. Chabert C, Knochbin S, Rousseaux S, Veyrenc S, Furze R, Smithers N, et al. Inhibition of BET proteins reduces right ventricle hypertrophy and pulmonary hypertension resulting from combined hypoxia and pulmonary inflammation. Int J Mol Sci 2018;19:E2224.

13. Piquereau J, Boet A, Péchoux C, Antigny F, Lambert M, Gressette M, et al. The BET bromodomain inhibitor I-BET-151 induces structural and functional alterations of the heart mitochondria in healthy male mice and rats. Int J Mol Sci 2019;20:E1527.

14. Van der Feen DE, Kurakula K, Tremblay E, Boucherat O, Bossers GP, Szulcek R, et al. Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med 2019;200:910–920.

15. Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Nat Acad Sci USA 2013;110:19754–19759.

16. Galdeano C, Ciulli A. Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology. Future Med Chem 2016;8:1655–1680.

17. Chiang CM. Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision. Chem Biol 2014;21:804–806.

18. Nicholls SJ, Ray KK, Johannson JO, Gordon A, Sweeney M, Halliday C, et al. Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs 2018;18:109–115.

19. Hooper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galé N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127:1128–1138.

20. Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kutlatse I, et al. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 2018;32:2224–2239.

In a recent issue of the Journal, we reported results from the first multicenter, preclinical study to show the therapeutic benefits of the BET (bromodomain and extratertimal motif) inhibitor RVX208 in multiple animal models of pulmonary arterial hypertension (PAH) (1). In their letter to the editor, Piquereau and Perros raised concerns about the potential cardiotoxic effects of BET inhibitors in patients with PAH based on published data demonstrating structural and functional alterations of the heart in healthy rodents treated with the pan-BET inhibitor I-BET-151 (2). A contrast must be drawn between highly potent, nonselective BET inhibitors such as I-BET-151, which are under development for oncology indications, and RVX208, which is a BD2-selective BET inhibitor with lower potency that has an excellent cardiovascular (CV) safety profile to date. A series of phase 2 studies evaluating RVX208 in a total of 789 patients with CV disease recently demonstrated a >40% reduction in major CV events (3). RVX208 is currently being evaluated in a phase 3 clinical trial involving 2,425 patients with high-risk type 2 diabetes and coronary artery disease (ClinicalTrials.gov identifier: NCT02586155). This study is being monitored by an independent data and safety monitoring board, which recommended that the study should continue as per protocol. To date, the total exposure in patients with high-risk CV disease is approaching 2,000 subjects, with no heart failure signal identified. To ensure the safety of the drug in the context of right ventricular dysfunction, we conducted experiments in a rat model of increased ventricular afterload induced by pulmonary artery banding. Treatment with RVX208 was not accompanied by deleterious effects, and, on the contrary, promoted the ventricular response to increased afterload (1). Combined, these results affirm a favorable safety profile of RVX208 for use in patients with PAH and PAH-associated right ventricular dysfunction and support the establishment of a clinical trial. Finally, as pointed out by Pullamsetti and de Jesus Perez, a comprehensive understanding of how domain- and isoform-selective BET inhibition can regulate specific transcriptional and biological responses will further refine its applications in the clinical arena.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Kondababu Kurakula, Ph.D.
Leiden University Medical Center
Leiden, the Netherlands

Olivier Boucherat, Ph.D.
Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec, Québec, Canada

Diederik E. Van der Feen, M.Sc.
University of Groningen
Groningen, the Netherlands

Harm Jan Bogaard, M.D., Ph.D.
Amsterdam University Medical Center
Amsterdam, the Netherlands

Ewelina Kulikowski, Ph.D.
Resverlogix Corp.
Calgary, Alberta, Canada

Beatriz Bartelds, M.D., Ph.D.
University of Groningen
Groningen, the Netherlands

Steeve Provencher, Ph.D.
Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec, Québec, Canada